Cibinqo (abrocitinib) / Pfizer, Glenmark - LARVOL DELTA

P098 Asthma control in patients receiving systemic therapy for atopic eczema: results from the UK Atopic eczema Systemic TherApy Register (A-STAR). (PubMed, Br J Dermatol) - "Treatments initiated at enrolment included dupilumab (n = 148), methotrexate (n = 66), Janus kinase inhibitors (abrocitinib or upadacitinib, n = 52) and ciclosporin (n = 37). We plan further, similar analyses on individual drug groups in relation to asthma control, as the number of A-STAR patients in individual drug groups increases over time, enhancing statistical power.TablePredictors of achieving good asthma control (Asthma Control Test 20-25) at week 16 in multivariable analysisVariableAdjusted odds ratio (95% confidence interval)aDrug groupJanus kinase inhibitors1 (reference)Ciclosporin3.32 (0.69-17.0)Dupilumab3.34 (1.28-9.03)*Methotrexate2.89 (0.78-11.4)Baseline asthma control test score1.31 (1.20-1.45)**P < 0.05. aAdjusted for baseline Eczema Area and Severity Index and Patient-Oriented Eczema Measure, number of prior oral systemic treatments, sex, age of atopic eczema onset, age of drug initiation and Fitzpatrick skin type."

Journal • Asthma • Atopic Dermatitis • Dermatology • Immunology • Pulmonary Disease • Respiratory Diseases

P122 Conducting federated treatment effectiveness analyses for systemic therapies in atopic dermatitis across country borders: methodological considerations from the DREAM TO TREAT AD project. (PubMed, Br J Dermatol) - "A novel federated statistical analysis approach for evaluating treatment effectiveness in patients with moderate-to-severe AD treated with abrocitinib and conventional systemic treatments has been developed and validated using synthetic data. As a next step, the analysis will be applied across the D2T AD consortium registers to generate valuable effectiveness results including sensitivity analyses regarding choice of visit windows."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus

P113 JAK in the box: unlocking real-world factors influencing Janus kinase inhibitor and dupilumab prescribing in atopic dermatitis. (PubMed, Br J Dermatol) - "A retrospective review was carried out of patients aged ≥ 12 years prescribed dupilumab or a JAKi (upadacitinib, abrocitinib or baricitinib) for AD in our tertiary dermatology centre between 2021 and 2024. Tralokinumab and lebrikizumab were excluded as all patients had prior dupilumab...Factors favouring dupilumab prescribing include older age, asthma status and cardiovascular risk factors. Factors favouring JAKi prescribing included speed of onset, ease of prescribing, younger age and needle phobia."

Journal • Real-world evidence • Retrospective data • Alopecia • Asthma • Atopic Dermatitis • Cardiovascular • Dermatitis • Dermatology • Dyslipidemia • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hypertension • Immunology • Inflammation • Inflammatory Bowel Disease • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Pain • Pulmonary Disease • Respiratory Diseases • Thrombosis • STAT2

BI02 Abrocitinib-induced Kaposi sarcoma in a patient with severe atopic dermatitis. (PubMed, Br J Dermatol) - "His medical history included asthma and gout, and prior treatments for his skin included ciclosporin, methotrexate and mycophenolate mofetil, all of which were discontinued due to treatment failure...Chemotherapy with doxorubicin (25 mg m-2 every 2 weeks) was initiated, with a planned total of 10 cycles...This case highlights the importance of close monitoring for malignancies in patients receiving JAK inhibitors, particularly those with extensive immunosuppressive treatment histories. Balancing disease control with the risks of malignancy poses a significant challenge in managing complex cases of severe AD."

Journal • Asthma • Atopic Dermatitis • Dermatitis • Dermatology • Epstein-Barr Virus Infections • Gout • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammatory Arthritis • Kaposi Sarcoma • Oncology • Pulmonary Disease • Respiratory Diseases • Rheumatology • Sarcoma • Solid Tumor • Transplantation

P088 Janus kinase inhibitor treatment in coexisting atopic dermatitis and irritable bowel disease: real-world experience and therapeutic outcomes. (PubMed, Br J Dermatol) - "Despite the apparent efficacy treating IBD in this series, only two of seven patients (29%) achieved satisfactory cutaneous response to JAKi monotherapy, contrasting with established efficacy data in isolated AD. These findings raise questions about underlying disease mechanisms in this phenotype, warranting further investigation.TableTreatment of seven patients with atopic dermatitis (AD) and irritable bowel disease (IBD) with Janus kinase inhibitors (JAKis)Age (years)Primary indicationBefore JAKi treatmentOn JAKi treatmentDisease statusAD treatmentIBD treatmentJAKi therapyOutcomes50ADEASI 54; UC controlledNoneGuselkumab (stopped)Upadacitinib 24 months (ongoing)EASI 75 achieved (5.1); UC remission22AD, CDEASI 41; CD activeMethotrexate (stopped)Infliximab (stopped)Upadacitinib 4 months (ongoing)EASI 75 achieved (7.4); CD remission29ADEASI 13; UC controlledNoneAZA, allopurinol (stopped)Upadacitinib 8 months (ongoing)EASI 10.3; added methotrexate (6 months), switched to..."

Journal • Real-world evidence • Alopecia • Atopic Dermatitis • Crohn's disease • Dermatitis • Dermatology • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Herpes Zoster • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • Varicella Zoster

P093 Switching patients who developed arthritis and/or enthesitis on dupilumab to tralokinumab: a case series. (PubMed, Br J Dermatol) - "Patient 2 developed bilateral shoulder, left Achilles tendon and back pain 2 years into dupilumab, which resolved when he switched to abrocitinib. To our knowledge, this is the first retrospective case series to report tralokinumab-associated inflammatory arthritis. These cases suggest that patients who develop arthritis or enthesitis on dupilumab are likely to experience similar symptoms on tralokinumab, and a treatment class switch (specifically to a Janus kinase inhibitor) can be beneficial.TablePatient characteristics Patient 1Patient 2Patient 3SexFemaleMaleFemaleAge (years)557028Eczema Area and Severity Index Baseline (pretreatment)23.630.329.5 On tralokinumab (month)6.1 (6)29.6 (4)2.1 (4)Arthropathy pattern Small joints+++ Large joints++-Enthesitis/tenosynovitis+++Ultrasound+N/A+CRP/ESRNormalN/ARaisedConcurrent managementNSAIDsN/ANSAIDsDuration of tralokinumab (months)13724Musculoskeletal symptom progressionImprovingResolvedImprovingTherapy after..."

Journal • Atopic Dermatitis • Back Pain • Dermatitis • Dermatology • Immunology • Inflammation • Inflammatory Arthritis • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Pain • Rheumatology • CRP • IL13

P117 Treatment and investigation of head and neck dermatitis in patients with atopic dermatitis treated with biologic and small-molecule therapies: a systematic review. (PubMed, Br J Dermatol) - "Improved/resolved HND was not reported per patient, but in one trial, the median time to 75% improvement in HND was 57 days for dupilumab (n = 238) vs. 29 days for abrocitinib 200 mg...Adverse HND was also reported for tralokinumab (3 of 49, 6%) and baricitinib (two of three, 67%)...Itraconazole led to clinical improvement in all cases that recurred on withdrawal...Future studies should compare head and neck outcomes between different biologics and JAKis. This will help improve treatment decisions for patients where HND is of particular concern."

Journal • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

BI35 A case of dupilumab-induced scalp psoriasis and review of the literature. (PubMed, Br J Dermatol) - "The AD was ineffectively controlled by topical steroids, ultraviolet therapy and abrocitinib. He was trialled on methotrexate (up to 12.5 mg per week), which helped control his eczema but was discontinued because of deranged liver function. He continued to develop severe recurrent flare-ups requiring treatment with short-term oral prednisolone and then ciclosporin...His AD is being managed with lebrikizumab...Hypothetically, the blockade of the T helper (Th)2 response with dupilumab by targeting the IL-4/IL-13 signalling pathway could result in a shift towards a Th1/Th17 phenotype, leading to an inflammatory cytokine cascade and eventually psoriatic skin plaques, as described in this report. Dermatologists should be aware of psoriasis as a potential adverse event with dupilumab."

Journal • Review • Allergic Rhinitis • Alopecia • Asthma • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • Mood Disorders • Psoriasis • Psychiatry • Pulmonary Disease • Respiratory Diseases • IL13 • IL4

O06 Association between novel systemic immunomodulatory medications and achievement of super response in patients with moderate-to-severe atopic eczema: results from the UK-Irish Atopic Eczema Systemic Therapy Register (A-STAR). (PubMed, Br J Dermatol) - "Patients in A-STAR who initiated conventional systemics (oral or subcutaneous methotrexate or ciclosporin), dupilumab or a JAK1 inhibitor (abrocitinib or upadacitinib) were included in this analysis. In conclusion, treatment with dupilumab and JAK1 inhibitors is associated with a higher proportion of patients with AE achieving super response, compared with methotrexate, despite these treatments being mainly used after failure of conventional systemic medication.TableAssociation between novel systemic immunomodulatory medications and achieving super response in patients with moderate-to-severe AE. Data are expressed as the hazard ratio (95% confidence interval) CrudeAdjustedMethotrexate1 (reference)1 (reference)Ciclosporin2.25 (0.59-8.52)2.79 (0.56-13.9)Dupilumab2.20 (1.04-4.69)3.03 (1.23-7.46)JAK1 inhibitors2.75 (1.58-8.36)5.89 (2.09-16.6)."

Journal • Observational data • Atopic Dermatitis • Dermatology • Immunology • Pruritus

Janus Kinase Inhibitors During Pregnancy and Adverse Drug Reactions: A Pharmacovigilance Disproportionality Analysis in VigiBase. (PubMed, Clin Transl Sci) - "This study analyzed VigiBase, the World Health Organization global pharmacovigilance database of individual case safety reports (ICSRs), to assess signals of disproportionate reporting (SDRs) for pregnancy-related adverse drug reactions (ADRs) reported with systemic JAKIs, including abrocitinib, baricitinib, deucravacitinib, fedratinib, filgotinib, itacitinib, momelotinib, pacritinib, peficitinib, ritlecitinib, ruxolitinib, tofacitinib, and upadacitinib. Findings should be interpreted cautiously given the limitations of spontaneous reporting systems and the exploratory nature of the analysis. Further studies are needed to better characterize the JAKI safety in pregnancy."

Adverse drug reaction • Adverse events • Journal • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

ADAIR: A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis. (clinicaltrials.gov) - P=N/A | N=183 | Recruiting | Sponsor: Pfizer | Trial completion date: May 2027 ➔ Dec 2027

Trial completion date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Targeting the JAK/STAT pathway in palmoplantar pustulosis: a review. (PubMed, Ann Med) - "Recent clinical case reports and early studies have shown favourable outcomes with JAK inhibitors, such as tofacitinib, upadacitinib, baricitinib, deucravacitinib and abrocitinib, in refractory PPP cases. JAK inhibitors emerge as a promising therapeutic strategy for PPP, due to their ability to block multiple inflammatory pathways simultaneously, especially where other cytokine-targeted therapies have failed. However, despite compelling early reports, larger controlled trials are essential to establish definitive efficacy, clarify long-term safety and optimize clinical use."

Journal • Review • Cardiovascular • Dermatology • Herpes Zoster • Immunology • Pain • Psoriasis • Varicella Zoster

Diversifying the triquinazine scaffold of a Janus kinase inhibitor. (PubMed, RSC Med Chem) - "Notably, compound (S,R,R)-40a emerged as a potent JAK1 inhibitor (IC50 = 18 nM), with similar potency as the FDA-approved inhibitors abrocitinib and upadacitinib. These findings highlight the potential of GDB-inspired molecules as a source for drug discovery."

Journal • JAK2 • JAK3 • TYK2

Efficacy of Tofacitinib in Alopecia Areata - Lucky Punch or Robust Treatment Option? (PubMed, Int J Trichology) - "This article presents the case of a 31-year old patient with alopecia areata, who after two subsequent treatments with Janus kinase-inhibitors Baricitinib and Abrocitinib, achieved therapeutic success after using tofacitinib. This case raises the question, whether tofacitinib could be a valid treatment option for the future."

Journal • Alopecia • Immunology

Dual Therapy for Atopic Dermatitis: How Lebrikizumab and JAK inhibitors are used in Tandem for Treatment Resistant Cases (ISDS 2025) - "Five patients discontinued dual therapy: three transitioned to an alternative combination regimen (Cibinqo/Abry, Rinvoq/Dupixent, Cibinqo/Ebglyss) and two reverted to monotherapy due to AD control and simplifying regimen or to minimize side effects. AD management requires individualized approaches, particularly in patients who do not respond to conventional therapies. Combinations, such as Lebrikizumab plus a JAK inhibitor, may expand treatment options for refractory cases. In this cohort, dual therapy demonstrated encouraging efficacy and acceptable tolerability, highlighting the need for larger studies to further define its role in AD management."

Clinical • Acne Vulgaris • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • Pruritus • IL13 • IL4

Successful treatment of refractory erosive lichen planus with abrocitinib: A case report. (PubMed, SAGE Open Med Case Rep) - "We report the case of a 62-year-old woman with severe and refractory erosive lichen planus involving the oral, genital, and esophageal mucosa, who failed multiple systemic treatments. Initiation of abrocitinib, a selective Janus Kinase 1 inhibitor, led to complete and sustained clinical remission."

Journal • Dermatology • Dermatopathology • Inflammation • Lichen Planus

Xanthoma Disseminatum in the Largest Single-Center Real-World Cohort: Over Five Years of Follow-up (ISDS 2025) - "Regimens included cladribine and real-world non-cladribine strategies (some incorporating sirolimus, abrocitinib, or trametinib). This largest single-center XD cohort with long follow-up supports a pragmatic care pathway: cladribine induction with rapid onset and no observed progression, multidisciplinary baseline evaluation given frequent mucosal/airway and pituitary involvement, and cladribine re-induction at relapse. Non-cladribine strategies also achieved high overall responses, although drug-specific estimates are limited by small numbers. The cycle-indexed, infection-aware monitoring framework is readily adoptable, and the immune signals warrant prospective validation."

Clinical • Real-world • Real-world evidence • Endocrine Disorders • Infectious Disease • Metabolic Disorders • IL6 • TNFA

Refractory Lichen Amyloidosis Coexisting With Atopic Dermatitis Responsive to Sequential Janus Kinase Inhibitor Therapy: Upadacitinib Followed by Abrocitinib. (PubMed, Kaohsiung J Med Sci) - No abstract available

Journal • Amyloidosis • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

An Abrocitinib Surrogate Molecule Reduces Disease Severity and Protects Skin Barrier Integrity in a Humanized Mouse Model of Atopic Dermatitis Flare-Ups (ISDS 2025) - "In summary, ASM reduced stress-induced AD flare severity and improved barrier integrity in humanized AD skin xenografts. These results support that keratinocyte responses to Abro may contribute to its ability to prevent flares, potentially through enhancement of skin barrier integrity in addition to focused anti-inflammatory effects."

Preclinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • CLDN1 • CLDN8 • CXCL1 • CXCL10 • CXCL9 • FLG • HRNR • KRT1 • S100A8

Abrocitinib impact on memory T cell subsets in Atopic Dermatitis: In vitro and ex vivo findings (ISDS 2025) - "By 144 hours, Abro also reduced CD3+CD45RO+CLA+ TRM cells in the lesional dermis, suggesting longer treatment durations are necessary for shifting TRM populations in the dermis. Combined, the data suggest that Abro influences the expansion and survival of TCl- and TRM cells, potentially resulting in breakthrough flare frequency delays and prevention of lesion extension."

IO biomarker • Preclinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • CCR4 • CD69 • CD8 • FLG • GATA3 • IL6 • IL9 • ITGAE

Comparative Ocular Safety of Dupilumab and Oral JAK Inhibitors in Atopic Dermatitis: A Real-World Propensity-Matched Analysis (ISDS 2025) - "Adults aged 18–89 years with AD who initiated dupilumab or an oral JAK inhibitor (upadacitinib or abrocitinib) within one year of diagnosis were included. In this large real-world cohort, dupilumab use in AD was associated with significantly increased risks of conjunctivitis and keratitis compared with oral JAK inhibitors, while rates of other ocular outcomes were similar. These findings underscore the need for proactive ophthalmic monitoring in patients initiating dupilumab therapy."

Clinical • Real-world • Real-world evidence • Atopic Dermatitis • Cataract • Conjunctivitis • Dermatitis • Dermatology • Dry Eye Disease • Immunology • Inflammation • Keratitis • Ocular Infections • Ocular Inflammation • Ophthalmology • Uveitis

JAK1 Signaling Is Involved in the Induction of Mechanical Alloknesis in Atopic Dermatitis. (PubMed, Biomedicines) - "The mice were then orally treated with one of three JAK inhibitors: the JAK1/2 inhibitor baricitinib, the JAK1-selective inhibitor abrocitinib, or the JAK2-selective inhibitor AZ960. These results suggest that JAK1 signaling plays a critical role in the induction of m-alloknesis in AD. Selective JAK1 inhibition is a promising therapeutic strategy for attenuating m-alloknesis and improving quality of life for patients with AD, independent of general skin inflammation and barrier function."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • Psoriasis • JAK1

Real-World Evidence of Effectiveness and Safety of Abrocitinib, Baricitinib and Upadacitinib in Atopic Dermatitis: A Systematic Review and Meta-Analysis. (PubMed, Am J Clin Dermatol) - "Data from real-world studies of JAKis in AD show effectiveness and safety similar to clinical trials using the highest treatment doses. It is important to be aware of HSV and acne risk as these AEs are the most common reasons for discontinuation. Interpretation of results was complicated by the lack of studies reporting dosage information."

HEOR • Journal • Real-world evidence • Retrospective data • Review • Acne Vulgaris • Atopic Dermatitis • Dermatitis • Dermatology • Herpes Simplex • Immunology • Pruritus

Abrocitinib for Head and Neck Dermatitis: Case Series and Literature Review. (PubMed, Clin Cosmet Investig Dermatol) - "Despite conventional therapies, including topical corticosteroids, calcineurin inhibitors, and biologics such as dupilumab, many patients remain refractory to treatment...To evaluate the efficacy of abrocitinib in refractory HND and compare its effectiveness with other JAK inhibitors (upadacitinib, baricitinib)...JAK inhibitors, particularly abrocitinib and upadacitinib, may be considered as first-line therapies for refractory HND. They offer both rapid symptom relief and sustained efficacy."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Improvement of Low-Dose Abrocitinib-Resistant Lichen Amyloidosis with Dupilumab: Two Case Reports. (PubMed, Clin Cosmet Investig Dermatol) - "This is the first report of dupilumab's efficacy after low dose abrocitinib failure in LA, suggesting its potential as a therapeutic option for refractory cases. Further studies are needed to confirm these findings."

Journal • Amyloidosis • Dermatology • Dermatopathology • Herpes Simplex • Inflammation • Pruritus • IL13 • IL4